Association between fluorine-18–labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas

Restricted access


Oligodendroglial tumors harboring combined 1p and 19q loss (1p/19q LOH) are characterized by a favorable prognosis and response to chemotherapy and radiotherapy, but detection of 1p/19q LOH relies on postoperative procedures. The authors investigated the potential of fluorine-18–labeled fluorodeoxyglucose (FDG) uptake in positron emission tomography (PET) to predict 1p/19q LOH preoperatively in tumors whose appearance on initial magnetic resonance images was consistent with that of low-grade glioma.


The study population comprised 25 patients who had undergone preoperative FDG-PET followed by tumor resection. Neuronavigation ensured a precise match of FDG uptake wi th the site of biopsy. All tumor specimens were graded according to the World Health Organization (WHO) classification system. Microsatellite analysis was used to identify 1p/19q LOH.

In this series, 16 of 25 gliomas corresponded to WHO Grade II. In eight of these 16, 1p/19q LOH was detected. Raised glucose utilization within the tumor was seen in the six of eight WHO Grade II gliomas with 1p/19q LOH and in none of the WHO Grade II gliomas without this genetic alteration (p = 0.003).


These findings demonstrate the potential of FDG-PET to predict 1p/19q LOH in WHO Grade II gliomas.

Abbreviations used in this paper:FDG = fluorine-18–labeled flu-orodeoxyglucose; LOH = loss of heterozygosity; MR = magnetic resonance; PET = positron emission tomography; SPECT = single-photon emission computed tomography; WHO = World Health Organization; 1p/19q LOH = combined 1p and 19q LOH.

Article Information

Address reprint requests to: Florian Stockhammer, M.D., Klinik für Neurochirurgie, Campus Virchow-Klinikum, Charité–Universi-tätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. email:

© AANS, except where prohibited by US copyright law.



  • View in gallery

    Magnetic resonance and FDG-PET images and results of microsatellite analysis from two cases of histologically proven WHO Grade II oligodendroglioma. Upper: Case 10. Axial T2-weighted (A) and T1-weighted contrast-enhanced (B) MR images. An FDG-PET image (C) showing low FDG uptake in an area corresponding to the tumor mass in the left temporal lobe. The results of microsatellite analysis (D) demonstrating the presence of both parental alleles in tumor DNA (TU) and blood DNA from peripheral lymphocytes (BL). Lower: Case 13. Axial T2-weighted (E) and T1-weighted contrast-enhanced (F) MR images. An FDG-PET image (G) showing high FDG uptake in an area corresponding to the tumor mass in the right parietal lobe. The results of microsatellite analysis (H) revealing 1p/19q LOH.



Alavi JBAlavi AChawluk JKushner MPowe JHickey W: Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62:107410781988


Atlas SWLavi EFisher PGIntraaxial brain tumors. Atlas SW: Magnetic Resonance Imaging of the Brain and Spine ed 3PhiladelphiaLippincott Williams & Wilkins2002. 565694


Cairncross JGUeki KZlatescu MCLisle DKFinkelstein DMHammond RR: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:147314791998


Cantuaria GFagotti AFerrandina GMagalhaes ANadji MAngioli R: GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 92:114411502001


Cavenee WKFurnari FBNagane MHuang HJSNewcomb EWBigner DD: Diffusely infiltrating astrocytomas. Kleihues PCavenee WK: Pathology and Genetics of Tumours of the Nervous System ed 1LyonIARC Press2000. 1021


Chahlavi AKanner APeereboom DStaugaitis SMElson PBarnett G: Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 61:2672732003


De Witte OLefranc FLevivier MSalmon IBrotchi JGoldman S: FDG-PET as a prognostic factor in high-grade astrocytoma. J Neurooncol 49:1571632000


Derlon JMPetit-Taboue MCChapon FBeaudouin VNoel MHCreveuil C: The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery 40:2762881997


Di Chiro GDeLaPaz RLBrooks RASokoloff LKornblith PLSmith BH: Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 32:132313291982


Hartmann CMueller WLass UKamel-Reid Svon Deimling A: Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 64:10142005


Henn WCremerius UHeide GLippitz BSchroder JMGilsbach JM: Monosomy 1p is correlated with enhanced in vivo glucose metabolism in meningiomas. Cancer Genet Cytogenet 79:1441481995


Kaschten BStevenaert ASadzot BDeprez MDegueldre CDel Fiore G: Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methio-nine. J Nucl Med 39:7787851998


Kim CKAlavi JBAlavi AReivich M: New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol 10:85911991


Kurokawa TYoshida YKawahara KTsuchida TOkazawa HFujibayashi Y: Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 109:9269322004


Lamonica DGrossman ZKlippenstein DWang HVilani JNabi HA: A comparative study of 511 keV SPECT and PET using separate 370 MBq F-18-FDG doses on different days. Clin Positron Imaging 2:81911999


Meyer PTSchreckenberger MSpetzger UMeyer GFSabri OSetani KS: Comparison of visual and ROI-based brain tumor grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med 28:1651742001


Muacevic AUhl ESteiger HJReulen HJ: Accuracy and clinical applicability of a passive marker based frameless neuronavigation system. J Clin Neurosci 7:4144182000


Muller PHenn WNiedermayer IKetter RFeiden WSteudel WI: Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas. Clin Cancer Res 5:356935771999


Padma MVSaid SJacobs MHwang DRDunigan KSatter M: Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64:2272372003


Shimizu TSaito NAihara MKurihara HNakazato YUeki K: Primary spinal oligoastrocytoma: a case report. Surg Neurol 61:77812004


Shows TBEddy RLByers MGFukushima YDehaven CRMurray JC: Polymorphic human glucose transporter gene (GLUT) is on chromosome 1p31.3–p35. Diabetes 36:5465491987


Smith JSPerry ABorell TJLee HKO'Fallon JHosek SM: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:6366452000


von Deimling ABender BJahnke RWaha AKraus JAlbrecht S: Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q. Cancer Res 54:139714011994


Walker Cdu Plessis DGFildes DHaylock BHusband DJenkinson MD: Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 10:718271912004


Cited By



All Time Past Year Past 30 Days
Abstract Views 44 44 14
Full Text Views 132 132 7
PDF Downloads 46 46 5
EPUB Downloads 0 0 0


Google Scholar